Provided by Tiger Fintech (Singapore) Pte. Ltd.

Addex Therapeutics Ltd

7.54
+0.44006.20%
Post-market: 7.53-0.0100-0.13%16:00 EDT
Volume:5.35K
Turnover:40.34K
Market Cap:8.06M
PE:1.01
High:7.89
Open:7.41
Low:6.90
Close:7.10
Loading ...

Company Profile

Company Name:
Addex Therapeutics Ltd
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
23
Office Location:
Chemin des Mines, 9,Geneva,Geneva,Switzerland
Zip Code:
1202
Fax:
41 22 884 1556
Introduction:
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Directors

Name
Position
Tim Dyer
Chief Executive Officer and Director
Vincent Lawton
Chairman
Roger Mills
Chief Medical Officer and Director
Isaac Manke
Director
Jake Nunn
Director
Raymond Hill
Director

Shareholders

Name
Position
Tim Dyer
Chief Executive Officer and Director
Jean Philippe Rocher
Head of Discovery-Chemistry
Lenaic Teyssedou
Head of Finance
Robert Lutjens
Head of Discovery-Biology
Roger Mills
Chief Medical Officer and Director